68 results about "Calcitonin" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The inventors discovered that calcitonin gene-related peptide (CGRP) inhibitors reduce pain caused by bone fracture without impeding healing of the fracture. Accordingly, disclosed herein are methods for treating pain in a subject that has sustained a bone fracture, and the methods comprise administering a therapeutically effective amount of a CGRP inhibitor to the subject.

The present invention relates to a process for preparing the compound of Formula I in the form of a base or a salt thereof, and its use as an intermediate for the preparation of calcitonin gene- related peptide (CGRP) receptor antagonist active pharmaceutical ingredients, in particular zavegepant, where the compound of Formula I is the following: (I)

The application discloses a kind of light illumination methods for laying hens in later egg production stage.The method comprises: in the breeding process of laying hens in later egg production stage, using light source to emit blue light illumination or blue light and white light illumination to irradiate laying hens, so that the illumination can improve eggshell quality.The method of the application can up-regulate the expression of CaBP-D28k gene in eggshell gland of laying hens in later production stage, improve the ability of eggshell calcium deposition, regulate the secretion of parathyroid hormone PTH, calcitonin CT and other hormones, maintain the balance of blood calcium and blood phosphorus, and effectively improve the strength, thickness and weight of eggshell, so as to improve the eggshell quality of eggs produced by laying hens.The application can improve the calcium and phosphorus absorption capacity of laying hens, maintain the balance of calcium and phosphorus metabolism, and has low energy consumption, green energy-saving and environment-friendly advantages.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The invention relates to a calcitonin luminescence detection kit and a detection method and application thereof. Specifically, the invention provides the high-sensitivity calcitonin luminescence detection kit, the high-sensitivity calcitonin luminescence detection kit comprises a first reagent and a second reagent, and the first reagent comprises magnetic beads connected with first protein; the second reagent comprises alkaline phosphatase connected with the second protein. The kit improves the detection accuracy and the sample coincidence rate.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

This invention relates to the field of biomedical data processing technology, specifically to a stratification system for sepsis-related secondary invasive fungal infections based on laboratory data. The invention obtains the degree of static intestinal baseline damage by considering serum lactate concentrations at different historical testing times, temporal characteristics, and a preset maximum backtracking period; it obtains the cumulative dosage of antimicrobial drugs and the hourly cumulative distribution value of drug use based on the drug dosage distribution at different medication times within a neighborhood of the real-time trigger time; it obtains the overall degree of inflammation reduction and the hourly cumulative distribution value of inflammation regression based on the procalcitonin concentration distribution at testing times within a neighborhood; and it further obtains the net drug-induced intervention level. Based on the degree of static intestinal baseline damage and the net drug-induced intervention level, the fungal infection characteristics are stratified. This invention, by considering non-drug-induced interference, accurately obtains the comprehensive risk level of fungal infection, improving the effectiveness of fungal infection stratification.

The invention relates to an electrochemiluminescence sensor based on an intelligent controlled release-interface capture-self-enhancement mechanism and application of the electrochemiluminescence sensor in procalcitonin detection, and belongs to the technical field of electrochemiluminescence detection. Controllable release of signal molecules is achieved by packaging terpyridyl ruthenium through ZIF-8, meanwhile, a DNA layer rich in guanine is modified on an electrode interface, and the layer can serve as a nano trap to efficiently capture the signal molecules and can also serve as a co-reactant to achieve signal amplification. A DNA strand displacement reaction is utilized to regulate and control a target response release process, and detection is realized according to a quantitative relationship between the concentration of procalcitonin and an electrochemical luminescence signal. A labeling recovery method verifies that the recovery rate of the sensor in a human serum sample reaches 100.6-103.6%, good accuracy and precision are shown, and a reliable platform is provided for clinical detection of inflammatory markers.

Disclosed herein is a 4-phenyl-lH-pyrazolo[3,4-b]pyridine-5- carboxamide derivative of formula (I) as amylin and / or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight.

To provide a biomarker for determining the severity and / or activity of atopic dermatitis.SOLUTION: Disclosed is a biomarker comprising at least one selected from the group consisting of S100A6, S100A8, Lipocapin-2, Fibrinogen, Calcitonin, VWF, Cardiotrophin-1, CystatinA, FGF-18, and Ubiquitin + 1.SELECTED DRAWING: None

Disclosed herein are methods for subtyping patients with a respiratory infection (e.g., community acquired pneuomonia or severe acute respiratory infection) to identify likely responders to corticosteroid therapy. The methods involve analyzing values of a plurality of biomarkers, examples of which include a first biomarker selected from procalcitonin, IL-6, and TREM-1, and a second biomarker selected from Pentraxin-3, MIP-3α, IL-1ra, IL-8, and NGAL. The methods enable personalized treatment decisions for patients with respiratory infections, potentially improving patient outcomes by targeting corticosteroid therapy to those most likely to benefit while avoiding harm to non-responders.

The application discloses an inflammation infection compound quality control product and a preparation method and application thereof. The quality control product comprises a matrix liquid and inflammation markers. The matrix liquid contains human serum, a buffer, a protein protective agent, a plasticizing agent, amino acids, saccharides, a surfactant and a preservative. The inflammation markers include C-reactive protein, procalcitonin, serum amyloid A and interleukin-6. The quality control product is stable in performance, can be placed for 1 year under 2-8 DEG C and in the dark, and is suitable for combined detection of different inflammation items, is convenient for clinical operation, saves cost, and provides guarantee for the accuracy of clinical test results.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The invention discloses a silicon shell protected Escherichia coli multifunctional probe, a preparation method and application of the probe in inflammatory marker detection, the surface of Escherichia coli is sequentially coated with a layer of gold nanoparticles (AuNPs), a layer of silicon dioxide (SiO2) and two layers of quantum dots (QDs), and rapid monitoring of sepsis biomarkers is achieved. The SiO2 layer introduced into the EASi-QDs structure has dual functions of remarkably enhancing the structural stability of bacterial cells and effectively inhibiting the fluorescence quenching effect caused by Au NPs, so that the high sensitivity and accuracy of lateral flow immunochromatography (LFIA) detection are ensured. The EASi-QDs-LFIA has the functions of colorimetric qualitative detection and fluorescent quantitative analysis, and can be used for synchronously detecting two key sepsis markers, namely procalcitonin (PCT) and interleukin-6 (IL-6). The detection limits of the method on PCT and IL-6 respectively reach 29.5 pg / mL and 4.7 pg / mL, which are respectively improved by at least 15 times and 339 times compared with the traditional enzyme-linked immunosorbent assay (ELISA) and gold nano colorimetric method.

A method in which gepants (antagonists of calcitonin gene related peptide (CGRP) receptor) are used for direct treatment of nausea and vomiting including chemotherapy-induced nausea and vomiting (CINV). Among them, drugs frequently prompt nausea and vomiting, such as antitumor chemotherapeutics which often cause CINV which in turn can severely compromise efficacy of therapy, as well as patient quality of life. The method uses antagonists of the CGRP receptor recently approved for migraine treatment to target calcitonin gene related peptide (CGRP), a neuropeptide with pleiotypic effects in the human body to prevent and counteract drug-induced nausea and vomiting including CINV.

Provided are Calcitonin gene-related peptide (CGRP) analogues comprising an N- terminal modification.

This application discloses compounds of formula I for modulating the activity of calcitonin receptors and / or amylin receptors, as well as pharmaceutical compositions comprising the compounds disclosed herein. Methods for treating diseases or disorders related to calcitonin receptors and / or amylin receptors are also provided.

Provided herein are nucleic acids, recombinant adeno-associated virus (rAAV) particles, and compositions, as well as methods of use thereof for transducing medullary thyroid carcinoma cells and in treatment of disease, such as medullary thyroid carcinoma. In some aspects, the nucleic acid comprises a truncated calcitonin promoter, which is optionally encapsidated within a rAAV particle. In other aspects, the rAAV particle is a rAAV particle having a mutation in a surface-exposed amino acid, such as tyrosine, threonine, or serine, that enhances transduction of the particle into medullary thyroid carcinoma cells.

The invention provides a fusion polypeptide, a kit and a detection method for procalcitonin detection. The provided SCFV antibodies fused to the large subunit and the small subunit of luciferase respectively can provide the best detection effect. When the fusion polypeptide is used for detecting the procalcitonin or the analogue thereof, excellent clinical comparison correlation is achieved, the detection time is shorter, the detection speed is higher, and a matched instrument is simple in structure.

This invention belongs to the field of biotechnology, specifically relating to the application of calcitonin in promoting fish growth. By constructing a fish model lacking calcitonin synthesis function and combining this with experiments treating wild-type fish with exogenous calcitonin, the weight and body length of the fish model lacking calcitonin synthesis function were measured. The results showed that calcitonin significantly enhanced the weight and body length of zebrafish. Therefore, calcitonin can be applied to promote fish growth.

A diagnostic reagent for quantitatively determining procalcitonin in a sample, suitable for simple photometric turbidimetric analysis and with high sensitivity for quantitatively determining procalcitonin in a sample, comprising an aqueous suspension of polymer particles to which an antibody against procalcitonin is covalently bound, wherein the tendency for aggregation / sedimentation is not detectable or is negligible even after prolonged standing, and the specific reactivity of the particles remains substantially unchanged. To provide such a diagnostic reagent, it is proposed according to the present invention that the suspended polymer particles have an average particle size in the range of 150-450 nm, the suspension comprises a proportion of dissolved sugar or sugar alcohol in the range of 25-250 g / l, and the suspension has a pH in the range of 8-10.

The invention discloses a chemiluminiscence detection kit for calcitonin. The chemiluminiscence detection kit comprises carboxyl magnetic nanoparticles coated by streptavidin, a calcitonin monoclonal antibody-1 labeled by acridinium ester, and a calcitonin monoclonal antibody-2 labeled by biotin. According to the chemiluminiscence detection kit for the calcitonin, the chemical substances, namely the cane sugar and the benzamidine hydrochloride, are added into the reagent, so that the influence of the procalcitonin in a sample on a test is reduced, and the stability and the specificity of the kit are greatly improved.

The invention relates to a calcitonin analogue and a derivative or pharmaceutically acceptable salt thereof. The invention relates to a pharmaceutical composition, which contains analogues or derivatives or pharmaceutically acceptable salts thereof, and further comprises pharmaceutically acceptable auxiliary materials. The analogues or derivatives or pharmaceutically acceptable salts and compositions of the analogues or derivatives are applied to the field of disease prevention / treatment.